Methods: Influenza A & B and Influenza A Subtyping assays ported to the JBAIDS instrument were performed using the Platinum Path Sample Purification Kit (BioFire Diagnostics, Inc.). Reagents were freeze-dried into a single tube containing all necessary constituents (primers, probe, enzyme, and buffers) for real-time PCR that can be stored at ambient temperature. A total of four diagnostic PCR assays were used against cultured strains of influenza A (H3N2, H3N2v, and H7N9) to verify that the JBAIDS Influenza A & B Typing Kit and Influenza A Subtyping Kit can detect the viruses accurately. Subsequently, the assays were evaluated for cross-reactivity with other influenza strains, as well as accuracy, precision, and limit of detection (LOD) for the two emergent strains using both cultured material and clinical samples.
Results: The study demonstrated that the JBAIDS Influenza A & B and Influenza A Subtyping kits are comparable to the CDC method of detection for the H3N2v and H7N9 strains. The influenza assay kits showed no cross-reactivity against adenovirus, influenza B, or negative clinical samples when tested.
Conclusion: We confirmed the JBAIDS Influenza kits’ ability to detect both the H3N2v and H7N9 viruses with accuracy and precision. The capability of comprehensive detection of virus strains of concern will allow the DoD to remain prepared in the face of a new influenza emergence and respond with appropriate treatments and effective preventive measures.
G. Brice, None
See more of: Poster Abstract Session